Cover Image
Market Research Report

Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers

Published by BCC Research Product code 667515
Published Content info 23 Pages
Delivery time: 1-2 business days
Price
Back to Top
Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers
Published: July 20, 2018 Content info: 23 Pages
Description

Highlights:

Adoptive Cell Therapies (ACTs) and the infusion of autologous or redirected tumor-specific T-cells have the potential to drastically impact the treatment of a variety of cancers, especially common epithelial cancers. This report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.

Report Scope:

The report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.

Report Includes

  • An overview of both the problems and phenomenal opportunities with cell therapy and immunotherapy in general. While there are several biological and also commercial issues still to more completely resolve, perhaps the largest challenges are scalability and compatibility. Most developers begin by creating cell therapies for smaller groups of individuals, and then when they see real promise, the issue of scalability is addressed
  • Detailed description about Adoptive Cell Therapy (ACT), how it targets the somatic mutations by infusion of autologous or redirected tumor-specific T-cells and its impact on the treatment of several metastasized malignancies
  • A brief examination of the patent landscape
  • Insight into the structure and function of T lymphocytes, identification of the different types of T lymphocytes as well as identifying the T Cell growth factor
  • Coverage of number of clinical trials being conducted to investigate the safety and efficacy of Tumor-Infiltrating Lymphocytes (TILs) and investigate their use
  • Evaluation of methods to improve TIL yield and tumor reactivity e.g. blockage of programmed cell death 1 (PD-1) and the effect of an agonistic 4-1BB antibody on TIL growth
Table of Contents
Product Code: BIO171A

Table of Contents

Chapter 1: Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes

  • Key Findings
  • Tumor-Infiltrating Lymphocytes (TILs): A New and Exciting Era in Cancer Treatments
  • Adoptive Cell Transfer (ACT) and Therapeutic TILs
    • Ground-Breaking Management of Advanced Metastatic Breast Cancer
    • Successful Advances in TILs Therapies for Cholangiocarcinoma
    • Hope for Immunotherapy Treatments of Gastrointestinal Cancers
  • Limitations of ACT and Therapeutic TILs
  • Overcoming the Limitations of ACT and Therapeutic TILs
  • Expanding Clinical Trial Portfolio
  • Complexities of the TILs Patent Landscape
  • What's Next for TILs?
  • Outlook and Implications

Chapter 2: References

Chapter 3: A Note from the Editor

Chapter 4: Analyst Credentials

List of Tables

  • Table 1: Overview of PD-1/PD-L1 inhibitors, Mechanisms of Action, Trial Designations and Approved Companion Diagnostics
  • Table 2: Commonly Used Acronyms Associated with Adoptive Transfer of Autologous TILs Therapy

List of Figures

  • Figure 1: Schematic of Adoptive Cell Transfer (ACT) Therapies
  • Figure 2: Schematic of Tumor-Infiltrating Lymphocytes (TILs) Therapies
  • Figure 3: Number of Clinical Trials Incorporating Tumor-Infiltrating Lymphocytes (TILs) Activity, by Phase and Year, by Study Start Date, 2005-2018*
  • Figure 4: Clinical Pipeline Iovance Biotherapeutics
Back to Top